Intelligent Control Approach to Anemia Management

贫血管理的智能控制方法

• 批准号: 7920591
• 负责人: ADAM E GAWEDA
• 金额: $ 5.4万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-23 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7920591
• 关键词: Adverse event; Algorithms; Anemia; Anti-Arrhythmia Agents; Artificial Intelligence; Arts; Biological Models; Biological Neural Networks; Biomedical Engineering; Blood; Blood Vessels; Caring; Chronic; Clinical; Clinical Research; Collection; Complex; Computer Assisted; Computer Simulation; Computer software; Computing Methodologies; Controlled Clinical Trials; Data; Decision Support Systems; Development; Dialysis procedure; Disease; Doctor of Philosophy; Dose; Drug Prescriptions; Effectiveness; Electrical Engineering; End stage renal failure; Engineering; Enrollment; Epidemiology; Erythropoietin; Evaluation; Feedback; Frequencies; Funding; Goals; Guidelines; Hemodialysis; Hemoglobin; Hemoglobin concentration result; Human; Individual; Information Sciences; Insulin; Iron; Machine Learning; Measures; Medicine; Methodology; Methods; Morbidity - disease rate; Nephrology; Outcome; Patient Monitoring; Patients; Pharmaceutical Preparations; Physiological; Population; Process; Protocols documentation; Public Health Schools; Research; Research Personnel; Safety; Sampling; Savings; Techniques; Technology; Testing; Training; Training Programs; Translations; Universities; Veterans; Waran; Work; base; clinical practice; computer science; cost effectiveness; data management; experience; improved; insight; instructor; mathematical algorithm; novel; patient population; primary outcome; programs; recombinant human erythropoietin; research clinical testing; response; simulation; statistics; theories; tool

DESCRIPTION (provided by applicant): Management of anemia due to end-stage renal disease is a multifactorial decision process involving administration of recombinant human erythropoietin (rHuEPO) and iron, as well as assessment of other factors influencing the progress of the disease. This application aims at improving the cost-effectiveness of this process through the use of state-of-the-art numerical tools from control engineering and machine learning. The specific aims are the collection of anemia management data and development of new guidelines for period of measuring hemoglobin levels if necessary, development of individualized, computer-assisted approach to rHuEPO dosing based on modern control engineering and machine learning approach, evaluation of the developed tools through numeric simulation and assessment of the potential improvements in therapy and projected savings in rHuEPO utilization. The final aim is to provide a physical implementation and to perform a clinical evaluation of the developed methodology. The applicant, Dr. Adam E. Gaweda, is an Instructor of Medicine in the Department of Medicine, Division of Nephrology at the University of Louisville. His original training is in the field of electrical engineering (M.Eng.) and computer science (Ph.D.). The applicant plans to develop as an independent and well established researcher in the field of biomedical engineering with focus on translation of state-of-the-art technology to heath care. To achieve this goal the applicant will enroll into the Clinical Research, Epidemiology and Statistics Training (CREST) Program at the University of Louisville, School of Public Health and Information Sciences

描述（由申请人提供）： 终末期肾病所致贫血的管理是一个多因素决策过程，涉及重组人促红细胞生成素（rHuEPO）和铁的管理，以及影响疾病进展的其他因素的评估。该应用旨在通过使用来自控制工程和机器学习的最先进的数字工具来提高该过程的成本效益。具体目标是收集贫血管理数据和制定新的指导方针，如有必要，测量血红蛋白水平的时期，开发个性化的，计算机辅助的方法，以现代控制工程和机器学习方法的基础上rHuEPO给药，通过数值模拟和评估开发的工具，在治疗和预计节省rHuEPO利用的潜在改进的评估。最终的目的是提供一个物理实现，并进行临床评价的开发方法。申请人亚当·E博士Gaweda是路易斯维尔大学医学系肾脏病学分部的医学讲师。他最初的训练是在电气工程领域（工程硕士）。计算机科学（PhD）申请人计划发展成为生物医学工程领域的独立和成熟的研究人员，专注于将最先进的技术转化为医疗保健。为了实现这一目标，申请人将参加路易斯维尔大学公共卫生和信息科学学院的临床研究，流行病学和统计培训（CREST）计划